Cited by 416Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic DiseasesNitric Oxide and Endothelin Effects

Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease

Open access
Caballero, A. Enrique·2003·Obesity Research

Abstract

Obesity, insulin resistance, and endothelial dysfunction closely coexist throughout the natural history of type 2 diabetes. They all can be identified not only in people with type 2 diabetes, but also in various groups at risk for the disease, such as individuals with impaired glucose tolerance, family history of type 2 diabetes, hypertension, dyslipidemia, prior gestational diabetes, or polycystic ovary syndrome. Whereas their evident association cannot fully establish a cause‐effect relationship, fascinating mechanisms that bring them closer together than ever before are rapidly emerging. Central or abdominal obesity leads to insulin resistance and endothelial dysfunction through fat‐derived metabolic products, hormones, and cytokines. Insulin resistance leads to endothelial dysfunction through the frequent association with traditional cardiovascular risk factors and through some more direct novel mechanisms. Some specific and shared insulin signaling abnormalities in muscle, fat, and endothelial cells, as well as some new genetic and nontraditional factors, may contribute to this interesting association. Some recent clinical studies demonstrate that nonpharmacological and pharmacological strategies targeting obesity and/or insulin resistance ameliorate endothelial function and low‐grade inflammation. All these findings have added a new dimension to the association of obesity, insulin resistance, and endothelial dysfunction that may become a key target in the prevention of type 2 diabetes and cardiovascular disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/oby.2003.174

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest. 1996;97:2601-10.
  2. Shimabukuro M, Koyama K, Chen G, et al. Direct antidi- abetic effects of leptin through triglyceride depletion of tis- sues. Proc Natl Acad Sci USA. 1997;94:4637-41.
  3. Libby P, Ridker PM, Maseri A. Inflammation and athero- sclerosis. Circulation. 2002;105:1135-43.
  4. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitiv- ity and atherosclerosis. Circulation. 1996;93:1809 -17.
  5. Pinkney JH, Stehower CD, Coppack SW, Judkin JS. En- dothelial dysfunction: cause of the insulin resistance syn- drome. Diabetes. 1997;46:S9 -13.
  6. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone on the endothelial function of the micro-and macrocirculation in patients with early and late type 2 diabe- tes. Metabolism. 2003;52:173-80.
  7. Ishibashi M, Egashira K, Hiasa K, et al. Anti-inflammatory and anti-atherosclerotic effects of pioglitazone. Hypertension. 2002;40:687-93.
  8. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondia- betic subjects. The BIGPRO1 Study. Diabetes Care. 1998;21: 1967-72.

Cited by

Sorted by citations

Authors
Caballero, A. E.
Affiliations
Joslin Diabetes Center (US)
Corresponding author
Caballero, A. Enrique
Venue
Obesity Research
Publisher
Wiley
Published
2003-11
Volume
11
Issue
11
Pages
1278-1289
ISSN
  • 1071-7323 (ISSN-L)
  • 1550-8528
OpenAlex
W2101835986
Cited by
416
References
92
Citations by year
2026: 5 · 2025: 5 · 2024: 16 · 2023: 9 · 2022: 6 · 2021: 19 · 2020: 9 · 2019: 17 · 2018: 10 · 2017: 17 · 2016: 19 · 2015: 23 · 2014: 30 · 2013: 26 · 2012: 19
FWCI
3.57
Type
journal article
Language
en
Open access
Locations
  • Obesity Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Keywords
endothelial dysfunction, obesity, insulin resistance, type 2 diabetes, abdominal obesity, adipokines, cytokines, insulin signaling, low-grade inflammation, cardiovascular risk factors, impaired glucose tolerance, polycystic ovary syndrome, diabetes prevention, cardiovascular disease prevention
MeSH terms
Diabetes Mellitus, Type 2, Endothelium, Vascular, Heart Diseases, Humans, Insulin Resistance, Obesity, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review